VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of
Bentley Systems (NASDAQ:BSY) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.14 by 64.29 percent. The company reported quarterly sales of $222.90 million which beat the